Navigation Links
Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
Date:1/4/2012

MORRISTOWN, N.J., Jan. 4, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it recently received approval from the US Food & Drug Administration to market Methylphenidate Hydrochloride Extended-Release Capsules (LA) CII, USP, 20mg, 30mg, and 40mg.  Actavis has first-to-file exclusivity on the 20mg, 30mg, and 40mg strengths. Distribution of the product has commenced. 

Methylphenidate Hydrochloride Extended-Release Capsules 20mg, 30mg and 40mg, the generic equivalent of Ritalin LA® 20mg, 30mg, and 40mg, had US sales of approximately $80.7 million for the 12 months ending September 30, 2011, according to IMS Health.   

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:

"The approval and launch of Methylphenidate Hydrochloride Extended-Release Capsules (LA) offers a significant value to our customers and patients.  This approval, along with the first-to-file exclusivity, also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace."

Please see prescribing information at www.actavis.us/methylphenidate.

About Actavis:

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Ritalin LA® is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
2. Actavis to Launch Novel Pain Medication in the US
3. QRxPharma Announces Strategic Partnership with Actavis
4. Actavis Launches Generic KADIAN® Capsules in the U.S.
5. Actavis Plans Latin America Expansion
6. Actavis Launches Generic Keppra XR® Tablets in the U.S.
7. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
8. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
9. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
10. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
11. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... HEIGHTS, Utah , Feb. 8, 2016 /PRNewswire/ ... and distributor of advanced-technology medical devices and rehabilitation ... related markets, congratulates the Denver Broncos, football team ... Kelvyn H. Cullimore Jr. , Chairman and Chief ... of excellence and we look forward to enhancing ...
(Date:2/8/2016)... 2016 --> ... Allied Market Research titled, "World Synthetic Biology ... estimates the world synthetic biology market to be ... technology segment would continue to lead the market ... collectively, held around half of the market share ...
(Date:2/5/2016)... OAKS, Calif. , Feb. 5, 2016 Amgen ... 5 th Annual Global Healthcare Conference at 9:15 a.m. ... York City . David W. Meline , executive ... at the conference. Live audio of the presentation can be ... , under Investors. A replay of the webcast will also ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated ... , Gary D. Radine, who recently retired as president and CEO of Delta Dental ... 2015 CEO of the Year , helped lead the effort to raise funds for ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... Facial Plastics, has added Kybella® to his medical and surgical expertise. Technically known ... approved FDA injectable medication used as a non-surgical alternative for reduction of fat ...
Breaking Medicine News(10 mins):